pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,216 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1862Endpoints1446Fierce Biotech764BioSpace754BioPharma Dive548raps249onclive165fda recalls
therapy area
allOncology12884Rare Disease3330Immunology3022Cardiology2847Hematology2294Pulmonology2253Vaccines
  • Pfizer signs $2.6 billion China deal to develop in-vivo CAR-T therapies for autoimmune disease
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to pursue in-vivo CAR-T cell therapies aimed at autoimmune disorders. Under the agreement, Pfizer will receive exclusive r…
    BioPharma Dive · 4h agoDealPositive↗ source
  • FDA issues complete response letter rejecting Summit Therapeutics' lung cancer drug
    The U.S. Food and Drug Administration released a complete response letter that rejects Summit Therapeutics' lung cancer candidate, providing the agency’s detailed reasons for the decision. The age…
    STAT · 5h agoCRLNegative↗ source
← prev
page 1 of 49
next →
119
fda medwatch114
globenewswire health73
fda press61
1853
Psychiatry & CNS1230
Ophthalmology1131
Endocrinology & Metabolism807
Pain791
Nephrology783
  • FDA rejects Summit Therapeutics' lung cancer drug ivonescimab, citing insufficient survival benefit
    The U.S. Food and Drug Administration issued a complete response letter rejecting the lung‑cancer therapy ivonescimab, which is being developed by Summit Therapeutics in partnership with Akeso. In…
    BioPharma Dive · 5h agoRegulatoryNegative↗ source
  • Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater China
    Pfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…
    Endpoints · 7h agoDealPositive↗ source
  • Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchase
    Merck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…
    Endpoints · 8h agoDealNegative↗ source
  • Trump administration withdraws Heidi Overton’s FDA nomination amid Senate support concerns
    The Trump administration has pulled the nomination of Heidi Overton to become the U.S. Food and Drug Administration commissioner, saying she lacked sufficient backing to win Senate confirmation. T…
    STAT · 5h agoRegulatoryNeutral↗ source
  • Debate Over Medical School Structure Emerges as U.S. Loses Measles Elimination Status
    A discussion is unfolding about whether the traditional four‑year medical school model should be broken into separate components. The idea was voiced by a medical student who asked if every part of…
    STAT · 7h agoNegative↗ source
  • FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancers
    The U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…
    BioPharma Dive · 1d agoApprovalPositive↗ source
  • Roche secures FDA approval for giredestrant, its first SERD for advanced breast cancer
    Roche announced that its experimental breast cancer drug giredestrant received FDA approval for treatment of patients with late‑stage disease. The approval places Roche into the selective estrogen…
    Endpoints · 1d agoApprovalPositive↗ source
  • GSK receives accelerated FDA approval for oral lung cancer drug neladalkib
    GSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
    Endpoints · 1d agoApprovalPositive↗ source
  • FDA approves Roche's new breast cancer drug, poised to become its top-selling product
    The U.S. Food and Drug Administration has granted approval to a new breast cancer therapy developed by Roche. This clearance paves the way for the drug's market launch. Roche says the medication c…
    STAT · 1d agoApprovalPositive↗ source
  • Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trial
    Sellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…
    STAT · 1d agoPositive readoutPositive↗ source
  • Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-S
    Sellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…
    Endpoints · 1d agoPositive readoutPositive↗ source
  • Capsida proposes new monkey testing framework after fatal gene therapy trial for brain disease
    Researchers presented investigations into a patient death that occurred in a gene therapy trial for a brain disease, which had raised concerns in the field. While the exact cause of death was not…
    STAT · 1d agoNegative readoutNegative↗ source
  • FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimab
    The U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…
    Endpoints · 23h agoRegulatoryNegative↗ source
  • AI drugmaker Isomorphic Labs raises $5 billion in Series C round
    Isomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…
    BioPharma Dive · 1d agoDealPositive↗ source
  • Marrow Therapeutics raises $173 million to develop infusion therapy for sickle cell disease
    Marrow Therapeutics was announced on Tuesday by biotech entrepreneur Romesh Subramanian. The new company aims to create an infusion therapy for sickle cell disease that matches the efficacy of gene…
    STAT · 1d agoDealPositive↗ source
  • Flagship invests £100 million to launch AI-native biotech platform hub in the United Kingdom
    Flagship announced it will allocate £100 million to establish a new biotech creation outpost in the United Kingdom. The outpost will focus on building AI-native platform companies that aim to addr…
    STAT · 1d agoDealPositive↗ source
  • Flavored nicotine tablets launch, raising concerns over appeal to youth
    New flavored nicotine tablets that melt in the mouth have been introduced by tobacco companies in several markets. Products include Zyn Melts by Philip Morris International in the United Kingdom…
    STAT · 1d agoNegative↗ source
  • U.S. loses measles elimination status, sparking political criticism of vaccination response
    International health officials from the Pan American Health Organization announced that measles is no longer considered eliminated in the United States. The designation, first achieved in 2000, is…
    STAT · 1d agoRegulatoryNegative↗ source
  • John Powers III named permanent director of NIH's National Institute of Allergy and Infectious Diseases
    NIH's National Institute of Allergy and Infectious Diseases (NIAID) has finally filled its top leadership vacancy that has persisted since 2025. The institute had been led in an acting capacity by…
    STAT · 1d agoNeutral↗ source
  • Eli Lilly inks up to $5.9 billion partnership with Stipple Bio to develop cancer therapies
    Eli Lilly announced a new collaboration with Cambridge-based biotech Stipple Bio, valued at up to $5.9 billion, aimed at creating novel cancer medicines. The agreement gives Lilly access to Stippl…
    Endpoints · 1d agoDealPositive↗ source
  • FDA approves Roche's Wilserdly for advanced HR-positive, HER2-negative breast cancer with ESR1 mutation
    The U.S. Food and Drug Administration has granted approval to Roche's new oral breast cancer therapy, Wilserdly (giredestrant). The decision clears the way for the drug's launch in the United State…
    STAT · 1d agoApprovalPositive↗ source
  • CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trial
    CG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…
    BioPharma Dive · 2d agoPositive readoutPositive↗ source
  • FDA rejects Summit Therapeutics' ivonescimab combo, citing lack of survival benefit in lung cancer
    Summit Therapeutics and partner Akeso received a rejection from the U.S. Food and Drug Administration for their PD-1/VEGF antibody ivonescimab combined with chemotherapy. The agency said the data d…
    BioPharma Dive · 2d agoRegulatoryNegative↗ source